What are the latest sterile infusion options?

September 11, 2025

Introduction

As healthcare experiences rapid innovation, sterile infusion options have become increasingly diverse and sophisticated. From home infusion therapies to the latest advancements in medical device sterilization, the landscape is constantly evolving to meet patient needs more effectively. This article delves into the latest sterile infusion options, focusing on current trends, technologies, and standards that are shaping the future of infusion therapy.

Overview of Sterile Injection Methods

What are the common types of infusion therapies?

Common types of infusion therapies include intravenous (IV), intramuscular (IM), and subcutaneous (SQ) infusions.

  • IV Infusions : Deliver fluids and medications directly into the bloodstream for immediate effects. This method is commonly used for a variety of treatments, including hydration and antibiotic administration.
  • IM Injections : Provide slower absorption as they are administered into muscle tissue. This approach is typical for vaccines and some hormonal treatments.
  • SQ Injections : Given into the fat layer beneath the skin, allowing for gradual absorption of medications, suitable for therapies such as insulin or certain biologics.

Sterility in manufacturing processes

The manufacturing of sterile injectables is crucial to ensure patient safety. There are two primary methods employed:

Method Description Common Applications
Terminal Sterilization Sterilization occurs at the end of the production process to eliminate contaminants. Used for most injectable solutions and equipment.
Aseptic Fill-Finish Maintains sterility throughout the filling process, vital for sensitive products. Common for biologics and products that can't withstand terminal sterilization.

Trends in the sterile injectables market

Several trends are influencing the sterile injectables market today:

  • An increase in chronic conditions has led to a rising demand for injectable therapies.
  • Biologics are becoming more prevalent, which drives interest in specialized sterile manufacturing processes.
  • The interest in self-injection therapies is on the rise, reflecting a shift towards more patient-centric care options, particularly important in home care settings.

This evolving field continues to adapt to regulatory advancements and technological improvements aimed at enhancing patient outcomes.

Home Infusion Therapy: Expanding Options

Home infusion therapy (HIT) market growth

The home infusion therapy market is projected to experience a significant annual growth rate of 7.5% through 2028. This growth reflects an evolving landscape where more patients can receive necessary treatments in the comfort of their homes rather than in hospitals. As a result, the market's estimated value has risen to approximately $19 billion, serving around 3.2 million patients annually. Such statistics underscore the increasing adoption of home infusion as a viable and effective treatment option.

Advantages and methods of home infusion

Home infusion offers numerous benefits, providing a cost-effective alternative to inpatient care while enhancing patient comfort and autonomy. Various administration methods include:

  • Intravenous push (IVP) : Quick administration for medications like ceftriaxone.
  • Elastomeric devices : Devices like the Easypump that ensure steady medication flow.
  • Ambulatory pumps : For continuous or intermittent infusion, promoting independence.

Each technique has its pros and cons regarding portability and flexibility. For instance, elastomeric pumps can enhance patient mobility during treatment, while ambulatory pumps offer continuous medication delivery. Ultimately, the choice of administration often hinges on factors such as medication stability, safety requirements, and patient preferences.

Types of IV Fluids and Their Uses

What are the main types of IV fluids?

The primary categories of IV fluids are crystalloids and colloids. Crystalloids are further classified by their tonicity:

  • Isotonic Solutions : Maintain fluid balance without shifting fluids between compartments. Commonly used options include:

    • 0.9% Normal Saline (NaCl) : Used for hydration and fluid volume deficit.
    • Lactated Ringer's Solution : Provides electrolytes and is used in surgical recovery.
  • Hypotonic Solutions : These solutions promote fluid movement into cells, which can be beneficial in specific scenarios but may lead to cellular swelling. An example is:

    • 0.45% Sodium Chloride : Used to treat cellular dehydration.
  • Hypertonic Solutions : They draw fluid out of cells, making them useful in managing conditions where fluid needs to be shifted. Notable examples include:

    • 3% Sodium Chloride : Used to treat hyponatremia by increasing serum sodium levels.

Applications of isotonic, hypotonic, and hypertonic solutions

The application of these IV fluids is crucial in various clinical settings:

Fluid Type Common Uses Clinical Situations
Isotonic Hydration Fluid volume deficit, surgical recovery
Hypotonic Cellular rehydration Treating cellular dehydration, not for head injuries
Hypertonic Serum sodium boost Managing hyponatremia, cerebral edema

These solutions are pivotal for restoring fluid and electrolyte balance, supporting patient recovery, and helping manage specific medical conditions.

Advancements in Sterilization Technologies

New sterilization methods

The landscape of sterilization technologies for medical devices is evolving, with several innovative methods making headway in ensuring safety without compromising product integrity. Ethylene oxide (EtO) gas remains a significant method, sterilizing about 50% of sterile medical devices in the U.S. It is especially useful for items made from specific polymers or those sensitive to heat.

Vaporized hydrogen peroxide (VHP) is now recognized as an Established Category A sterilization method by the FDA. This recent recognition emphasizes its effectiveness in maintaining sterility while being more environmentally friendly compared to traditional methods.

FDA initiatives for sterilization processes

To further modernize sterilization practices, the FDA has launched initiatives such as the Sterilization Master File Pilot Programs. These programs focus on implementing new technologies that enhance safety during the sterilization process, ultimately addressing rising environmental concerns. The advances aim to refine existing techniques while paving the way for safer practices across the industry.

Sterilization Method Description Advantages
Ethylene Oxide (EtO) Gas sterilization method Effective for heat-sensitive devices
Vaporized Hydrogen Peroxide (VHP) Utilizes vapor for sterilization Environmentally friendly and effective
Terminal sterilization Final sterilization process Comprehensive pathogen reduction
Aseptic fill-finish Maintains sterility throughout process Ideal for heat-sensitive products

These innovations underscore the commitment to enhance device safety while adapting to both clinical and environmental needs.

Shortages in IV Solutions and Management Strategies

Is there a shortage of IV solutions in 2024?

Yes, there is a shortage of IV solutions in 2024. The recent closure of Baxter International's manufacturing facility in North Carolina, which accounted for about 60% of the nation’s IV fluids, has caused significant disruption. This closure was necessitated by Hurricane Helene, leading to alarming reports from a survey conducted in early October. Over 86% of healthcare providers indicated they were facing shortages, with many stating that less than half of their orders were filled. Alarmingly, 54% of providers reported having only 10 days or less of stock on hand, a sharp decline from the previous stock levels of 15 to 22 days prior to the crisis. While the FDA has undertaken efforts to facilitate temporary imports, Baxter's facility is not expected to resume operations until mid- to late November.

What strategies are in place to manage the shortages?

In response to the IV fluid shortages, several strategies have been outlined by healthcare authorities, such as the American Society of Health Systems Pharmacists. Key approaches include:

  • Evaluating Clinical Needs : Providers are encouraged to assess the necessity of IV fluid replacements on a case-by-case basis to conserve supplies.
  • Exploring Alternatives : Exploring options for oral hydration when appropriate to reduce the demand for IV fluids.
  • Replenishing Inventories : Major suppliers like B. Braun Medical are actively working to replenish hospital inventories affected by these disruptions.
  • Flexibility with Product Uses : The FDA has approved extensions for the shelf life of over 50 intravenous and irrigation products, ensuring that available products can be used longer.

These strategies are vital in mitigating the impact of the current shortages and maintaining patient care standards.

Current Infusion Therapies and Administration Methods

What are the different types of IV drip infusions?

There are several types of IV drip infusions classified based on their tonicity:

  • Isotonic solutions : These maintain fluid balance without causing significant shifts in fluid between compartments. Common isotonic IV fluids include:

    • 0.9% Normal Saline (NaCl)
    • Lactated Ringer's solution
    • Dextrose 5% in Water (D5W)
  • Hypotonic solutions : Such as 0.45% Normal Saline and 2.5% Dextrose in Water, these are used to treat conditions like hypernatremia by allowing water to enter the cells.

  • Hypertonic solutions : This category includes 3% Sodium Chloride and Dextrose 50% in Water, which draw water out of cells, making them useful in cases like hyponatremia and cerebral edema.

  • Colloid solutions : Solutions like Human Albumin are utilized to expand intravascular volume and assist patients with significant fluid deficits.

Administrative devices and techniques

Administration methods vary widely and can affect patient comfort and treatment outcomes. Key devices include:

  • Intravenous push (IVP) : Ideal for quick administration of certain medications, like ceftriaxone.
  • Elastomeric devices : Devices such as Easypump and Homepump Eclipse offer a consistent flow rate, enhancing mobility for patients.
  • Ambulatory pumps : Options like the CADD-Solis provide flexibility in medication delivery, allowing for continuous or intermittent infusions.
  • Peripheral venous catheters (PVCs) : Used for short-term IV therapy, lasting 1 to 5 days.
  • Central venous catheters (CVCs) : Suitable for long-term access, enabling the administration of irritating medications and fluids over months to years.

These diverse options enable healthcare providers to select the most appropriate method based on patient needs, medication properties, and treatment duration.

Emerging Trends in Sterile Infusion Products

New products and innovations

The landscape of sterile infusion products is rapidly evolving, driven by advancements in technology and therapeutic needs. The NHIA has compiled an extensive list of over 350 medications used for intravenous (IV) or subcutaneous (SC) infusions. By categorizing these drugs into various classes with information on their generic and brand names, therapeutic categories, and hazardous designations, healthcare providers can make better-informed site-of-care decisions.

One standout development is the increased focus on home infusion therapy (HIT), which is projected to grow at an annual rate of 7.5% through 2028. This rise reflects a demand for cost-effective and patient-centered care, encompassing a wide range of therapies including antibiotics, chemotherapy, and biologics. Additionally, the streamlined application of elastomeric devices and ambulatory pumps, like the CADD-Solis for administering Remodulin, demonstrates the increasing sophistication and user-friendliness of home therapies.

Educational resources for healthcare professionals

To support the implementation of these innovations, various educational resources are available for healthcare professionals. The Infusion Therapy Standards of Practice, published every five years by the Infusion Nurses Society, provide crucial guidelines on the use and management of infusion devices. This includes not only the technical aspects but also emphasizes infection control through the new Aseptic Non Touch Technique (ANTT).

Furthermore, manufacturers and associations continue to create training programs focused on the complexities of preparing compounded sterile products (CSPs) in compliance with USP <797> guidelines. These resources ensure that healthcare providers are well-equipped to deliver safe and effective therapy amid evolving standards and practices in sterile infusion.

Regulatory Standards and Compliance

Infusion Therapy Standards

The Infusion Therapy Standards of Practice, published every five years by the Infusion Nurses Society (INS), establish a comprehensive guideline for infusion therapy. The latest 2021 standards address a broad range of infusion access devices including intravenous (IV), subcutaneous, intraosseous, and intraspinal access devices. These guidelines emphasize the need for healthcare professionals to be adequately trained and competent in administering infusion therapies, especially with increasing patient complexity in home healthcare settings.

Guidelines for Sterile Compounding

Compliance with USP <797> is crucial in ensuring safe sterile compounding practices, particularly for home infusion therapies. Compounded sterile products must be prepared in an ISO 5 environment or better, along with stringent monitoring of contamination risks. Beyond-use dates (BUDs) for these products vary based on their risk levels, ranging from 14 days for low risk to just 3 days for high-risk preparations. Primary Engineering Controls like laminar airflow workbenches are essential in maintaining cleanliness, thereby safeguarding patient health during the compounding process.

The Role of Vascular Access Devices in Infusion Therapy

Types of Vascular Access Devices

Vascular access devices (VADs) are critical tools for administering treatments in both hospital and home settings. They come in various forms, including:

  • Peripheral Venous Catheters (PVCs) : Ideal for short-term use, typically remaining in place for 1 to 5 days.
  • Midline Catheters : Suitable for intermediate therapy, used for up to 4 weeks. These are larger-gauge and can facilitate rapid infusions.
  • Central Venous Catheters (CVCs) : Designed for long-term treatment, these can be maintained for months or even years, essential for patients requiring continuous therapy or those receiving irritating medications.

Each type plays a unique role depending on the treatment plan and patient needs.

Considerations for Home Care Use

For home infusion therapy, the choice of VAD is crucial. Factors influencing selection include:

  • Duration of Treatment : Midlines are often favored for longer therapies, while PVCs may suffice for shorter treatments.
  • Medication Properties : Certain medications, particularly vesicants, require careful evaluation of VAD type to prevent complications.
  • Patient Safety : Compliance with protocols like USP <797> ensures safe sterile compounding in home settings. This compliance is vital for maintaining patient safety and preventing infections.

Careful selection of vascular access devices enhances the effectiveness of home infusion therapy, ensuring positive patient outcomes.

The FDA's Role in Ensuring Safe Sterile Practices

FDA Approval Processes

The FDA plays a crucial role in ensuring the safety and efficacy of medications administered through various infusion methods. This includes approving new drugs and extending the shelf life of existing products. As part of its strategy to tackle shortages, the FDA has authorized over 50 intravenous and irrigation products for extended shelf life, which aids in managing current supply challenges.

Additionally, the FDA recognizes innovative sterilization methods, such as vaporized hydrogen peroxide (VHP), as established sterilization processes. This recognition not only supports better sterilization techniques but also highlights the importance of maintaining safety and effectiveness in medical device manufacturing.

Safety and Efficacy in Infusion Methods

Moreover, adherence to the FDA’s guidelines for sterile injectable drugs is essential. Various sterile injectables must undergo stringent manufacturing processes to prevent contamination, often involving terminal sterilization or aseptic fill-finish methods. This ensures that medications delivered via home infusion therapy—and also those requiring intravenous therapy—meet safety standards critical for patient health.

The FDA’s initiatives are pivotal in advancing safer practices in medicine, thereby improving patient outcomes and fostering advancements in home infusion therapy. Their ongoing work to implement new technologies further enhances the safety, effectiveness, and reliability of infusion methods used in healthcare settings.

The Impact of Infusion Therapy on Healthcare Delivery

The evolution of infusion therapy

Infusion therapy has transformed significantly over the years, shifting from traditional inpatient settings to the home healthcare environment. Home infusion therapy (HIT) allows patients to receive essential medications safely within their homes, promoting comfort and convenience. This modality encourages better patient compliance and reduces healthcare costs associated with prolonged hospital stays.

As the landscape of home care evolves, the home infusion market is projected to grow at an annual rate of 7.5% through 2028, reflecting the increasing acceptance of HIT in treating conditions such as infections, immune deficiencies, and chronic diseases. With options like elastomeric devices and ambulatory pumps, patients can now manage their infusions with greater independence and flexibility.

Patient outcomes and healthcare efficiency

The integration of infusion therapy into patient's homes enhances clinical outcomes by facilitating timely treatment and minimizing hospital-associated risks, including infections and readmissions. Studies indicate that home antimicrobial infusion has emerged as the safest option compared to outpatient or inpatient facilities, particularly highlighted during the COVID-19 pandemic.

Healthcare efficiency also receives a boost through HIT. By alleviating the burdens on hospital resources, infusion therapy optimizes healthcare delivery, allowing clinicians to focus on critical care while providing patients with effective treatment regimens in a familiar environment. This approach not only improves patient satisfaction but fosters a more sustainable healthcare system, benefiting both patients and providers.

Challenges and Future of Home Infusion Therapy

Barriers to Home Infusion Adoption

Despite its many benefits, home infusion therapy (HIT) faces several barriers to wider adoption. One prominent challenge is the lack of trained healthcare professionals in home settings to manage complex therapies. Ensuring that home care nurses are competent in performing infusion-related procedures is critical. Additionally, there are concerns about the reliability of supply chains , especially highlighted during recent shortages of IV fluids. Current manufacturing and distribution issues affect timely access to necessary medications.

Moreover, patient safety concerns around sterility and administration can deter some providers from recommending home therapies. The necessity for stringent infection control practices , as outlined in the Aseptic Non Touch Technique (ANTT) guidelines, adds to the complexity of HIT.

Future Outlook and Technological Advancements

Looking ahead, the home infusion market shows promising growth with an expected annual growth rate of 7.5% through 2028 . Innovations such as the SPmix program aiming to offer premixed medications at home could enhance safety and ease of administration. Advances in technology, including more portable ambulatory pumps and simplified administration methods , are also making home infusions less cumbersome for patients.

In conjunction with these developments, the NHIA's continuous efforts to expand the list of covered medications and ensure their accessibility indicate a dedicated path towards enhanced home infusion services. As healthcare shifts towards more patient-centered models, home infusion is likely to become an increasingly viable option for managing chronic diseases and complex treatments effectively.

Conclusion

In summary, the field of sterile infusion therapy is witnessing transformative changes that are enhancing patient care and providing new opportunities for treatment. By staying informed on the latest developments, healthcare providers can ensure they are offering the most effective and safe options for their patients. As the industry continues to evolve, staying abreast of technological innovations, regulatory standards, and patient-centered approaches will be vital for success.

References

July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Home Infusion Therapy in New Jersey
July 14, 2026
Pharmko provides home infusion therapy across New Jersey, IV antibiotics, IVIG, TPN, IDPN, biologics, and more. Licensed, ACHC accredited, and available 24/7 statewide.
Renal dietitian reviewing albumin labs for a peritoneal dialysis patient
July 10, 2026
When to consider IPN for peritoneal dialysis patients with low albumin: clinical criteria, the stepwise nutrition approach, and the referral process.
Show More